Logo image of SQZ

SQZ BIOTECHNOLOGIES CO (SQZ) Stock Price, Quote, News and Overview

NYSE:SQZ - New York Stock Exchange, Inc. - US78472W1045 - Common Stock - Currency: USD

0.435  +0.16 (+61.11%)

After market: 0.4384 +0 (+0.78%)

SQZ Quote, Performance and Key Statistics

SQZ BIOTECHNOLOGIES CO

NYSE:SQZ (7/3/2023, 8:01:56 PM)

After market: 0.4384 +0 (+0.78%)

0.435

+0.16 (+61.11%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High3.56
52 Week Low0.25
Market Cap12.83M
Shares29.49M
Float21.51M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-02 2023-08-02/amc
IPO10-30 2020-10-30


SQZ short term performance overview.The bars show the price performance of SQZ in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 -40

SQZ long term performance overview.The bars show the price performance of SQZ in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of SQZ is 0.435 USD. In the past month the price decreased by -27.5%. In the past year, price decreased by -87.5%.

SQZ BIOTECHNOLOGIES CO / SQZ Daily stock chart

SQZ Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.26 362.28B
AMGN AMGEN INC 15.63 166.37B
GILD GILEAD SCIENCES INC 24.19 138.93B
VRTX VERTEX PHARMACEUTICALS INC 1663.07 123.90B
REGN REGENERON PHARMACEUTICALS 15.57 77.69B
ARGX ARGENX SE - ADR N/A 38.54B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.45B
BNTX BIONTECH SE-ADR N/A 28.09B
ONC BEIGENE LTD-ADR N/A 27.70B
NTRA NATERA INC N/A 21.35B
BIIB BIOGEN INC 8.54 20.50B
UTHR UNITED THERAPEUTICS CORP 15.91 16.17B

About SQZ

Company Profile

SQZ logo image SQZ Biotechnologies Co. is a clinical-stage biotechnology company, which engages in developing cell therapies for patients with cancer, infectious diseases, and other serious conditions. The company is headquartered in Watertown, Massachusetts and currently employs 53 full-time employees. The company went IPO on 2020-10-30. The firm is focused on unlocking the full potential of cell therapies to benefit patients. In oncology, it is developing cell therapy platforms that are based on directing tumor antigen-specific immune activation via engineered antigen presentation. Its clinical-stage cell therapy candidates include SQZ Enhanced APC (eAPC) Platform, SQZ Activating Antigen Carrier (AAC) Platform and SQZ Tolerizing Antigen Carrier (TAC) Platform. The SQZ eAPC platform is the second-generation product candidate designed to generate tumor specific CD8+ T cell activation to drive the antitumor immune response. The SQZ AAC platform is designed to induce antigen presentation in vivo by deriving antigen carriers from engineering red blood cells (RBCs) with tumor specific antigens and adjuvants. Its SQZ TAC platform is designed to induce antigen-specific immune tolerance in vivo by utilizing a similar approach to the AAC platform.

Company Info

SQZ BIOTECHNOLOGIES CO

200 Arsenal Yards Blvd, Suite 210

Watertown MASSACHUSETTS 02472 US

CEO: Armon Sharei

Employees: 53

Company Website: https://sqzbiotech.com/

Phone: 16177588672.0

SQZ BIOTECHNOLOGIES CO / SQZ FAQ

What is the stock price of SQZ BIOTECHNOLOGIES CO today?

The current stock price of SQZ is 0.435 USD. The price increased by 61.11% in the last trading session.


What is the ticker symbol for SQZ BIOTECHNOLOGIES CO stock?

The exchange symbol of SQZ BIOTECHNOLOGIES CO is SQZ and it is listed on the New York Stock Exchange, Inc. exchange.


On which exchange is SQZ stock listed?

SQZ stock is listed on the New York Stock Exchange, Inc. exchange.


What is the price forecast or stock price prediction for SQZ BIOTECHNOLOGIES CO stock?

6 analysts have analysed SQZ and the average price target is 19.38 USD. This implies a price increase of 4355.17% is expected in the next year compared to the current price of 0.435. Check the SQZ BIOTECHNOLOGIES CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is SQZ BIOTECHNOLOGIES CO worth?

SQZ BIOTECHNOLOGIES CO (SQZ) has a market capitalization of 12.83M USD. This makes SQZ a Nano Cap stock.


How many employees does SQZ BIOTECHNOLOGIES CO have?

SQZ BIOTECHNOLOGIES CO (SQZ) currently has 53 employees.


What are the support and resistance levels for SQZ BIOTECHNOLOGIES CO (SQZ) stock?

SQZ BIOTECHNOLOGIES CO (SQZ) has a resistance level at 0.52. Check the full technical report for a detailed analysis of SQZ support and resistance levels.


Is SQZ BIOTECHNOLOGIES CO (SQZ) expected to grow?

The Revenue of SQZ BIOTECHNOLOGIES CO (SQZ) is expected to grow by 65.7% in the next year. Check the estimates tab for more information on the SQZ EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy SQZ BIOTECHNOLOGIES CO (SQZ) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does SQZ BIOTECHNOLOGIES CO (SQZ) stock pay dividends?

SQZ does not pay a dividend.


When does SQZ BIOTECHNOLOGIES CO (SQZ) report earnings?

SQZ BIOTECHNOLOGIES CO (SQZ) will report earnings on 2023-08-02, after the market close.


What is the Price/Earnings (PE) ratio of SQZ BIOTECHNOLOGIES CO (SQZ)?

SQZ BIOTECHNOLOGIES CO (SQZ) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.45).


SQZ Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

SQZ Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to SQZ. The financial health of SQZ is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SQZ Financial Highlights

Over the last trailing twelve months SQZ reported a non-GAAP Earnings per Share(EPS) of -2.45. The EPS increased by 7.89% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%20%
Sales Q2Q%-100%
EPS 1Y (TTM)7.89%
Revenue 1Y (TTM)-24.08%

SQZ Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 77% to SQZ. The Buy consensus is the average rating of analysts ratings from 6 analysts.

For the next year, analysts expect an EPS growth of 19.72% and a revenue growth 65.7% for SQZ


Ownership
Inst Owners0.01%
Ins Owners10.69%
Short Float %N/A
Short RatioN/A
Analysts
Analysts76.67
Price Target19.38 (4355.17%)
EPS Next Y19.72%
Revenue Next Year65.7%